about https www milyon88 games

about https www milyon88 games Hugel aims to secure strong business coverage in the region via the strategic partnership The MENA aesthetic market is projected to witness strong growth in the next few years with UAE and Saudi Arabia taking the lead SEOUL, South Korea , Nov. 21, 2024 /PRNewswire/ -- Hugel Inc., a leading global medical aesthetics company, said on Friday it will spur expansion in the botulinum toxin market of the Middle East and North Africa (MENA) via a strategic partnership with Dubai -headquartered aesthetic and medical distribution partner Medica Group. The two companies have recently entered into an agreement to bolster the distribution of Hugel's toxin Botulax in the key markets of the region. Hugel, which exports its own toxin to 64 markets including the US, Europe and China , the world's three largest toxin buyers, obtained sales approval for Botulax in the Middle East last year. Medica Group is a leading player in the region and has strong distribution networks through its head office in the United Arab Emirates (UAE) and branches in Saudi Arabia and Lebanon . The company distributes medical aesthetic products from about 30 global brands, proving their solid know-how in the field and strong execution capabilities in the MENA. The MENA is one of the fastest growing regions for medical aesthetics, driven by strong economic momentum, favorable demographic characteristics, increasing accessibility to social media as well as social and consumption transformation. Hugel's Executive Chairman, Suk Cha , commented on the partnership: "We are very pleased to enter into this strategic collaboration with Medica Group. The Middle East represents a key market for Hugel, with its rapidly growing demand for medical aesthetic treatments. We have chosen Medica Group as our distributor because they share our commitment to excellence and quality. Their proven expertise, extensive reach and deep understanding of the region make them the ideal partner to bring our Botulax product to this dynamic region. Botulax is recognized globally for its quality, and we are confident that, through this partnership, it will become a leading choice for medical professionals and patients in the Middle East and Africa ." Andre Daoud , CEO of Medica Group, highlighted the importance of this collaboration: "Our partnership with Hugel marks a key milestone for us as we continue to expand our portfolio and lead the aesthetics market with global solutions. The introduction of Botulax in the Middle East and Africa offers healthcare professionals access to a world-class botulinum toxin that is highly trusted for its quality, safety, and performance. This strategic partnership aligns with our mission to provide advanced, innovative products and services that meet the demands of the region's growing beauty and medical aesthetics market. Hugel's global expertise, combined with our deep local knowledge and network, will create tremendous value for our customers and their patients." About Hugel Established in 2001, Hugel is a leading global medical aesthetics company that manufactures injectables for skin rejuvenation such as botulinum toxin, hyaluronic acid fillers and skin boosters as well as absorbable sutures and cosmetics products. The company is the only South Korean supplier to the world's three largest botulinum toxin markets, the US, China and Europe . It exports medical aesthetic products and devices to around 70 countries and operates eight global subsidiaries in the US, Australia , Canada , Taiwan , China , Hong Kong and Singapore . About Medica Group A leading partner in the field of aesthetic medicine, Medica Group continues to push the boundaries of beauty and wellbeing in the region. Being at the forefront of the industry, the group is renowned for its innovative approach, state-of-the-art solutions with a solid commitment to delivering outstanding results and setting new standards in aesthetics. A trusted partner for international aesthetic brands, Medica showcases a commitment to excellence and quality through the technologies of its product and services, and the collaboration of the aesthetic medicine community. Contact: Jihyun Kim , Manager of the PR Team, Hugel jihyun.kim@hugel-inc.com View original content to download multimedia: https://www.prnewswire.com/news-releases/hugel-and-medica-join-forces-to-boost-botulinum-toxin-sales-in-middle-east-north-africa-302313729.html SOURCE Hugel

Telix Pharmaceuticals: Australian Company And A Solid Recent U.S. IPODAZN ADVANCES GLOBAL EXPANSION WITH ACQUISITION OF FOXTEL, A LEADING AUSTRALIAN SPORTS AND ENTERTAINMENT MEDIA GROUP

BeyondTrucks Adds Orderful’s Data Platform Into Transportation SystemElon's revenge

AP News Summary at 4:42 p.m. ESTThe missing teenager who vanished in waters off NSW’s Central Coast on Christmas Eve has been identified as 15-year-old Luca Bennett. The teenager was playing with two other friends on rocks at North Avoca Beach when they were swept into the water just before 3pm on Tuesday. Two of the teens managed to get to shore safely however Bennett did not, with his friends alerting nearby lifeguards. A multi-agency search for the teenager commenced with the help of the Brisbane Water Police District, Marine Area Command, NSW Ambulance, Surf Life Saving NSW, Marine Rescue NSW and the Westpac Rescue Helicopter. The search resumed on Christmas Day, with emergency services crews seen searching near rocks and in the water on jet skis. The NSW Police Airwing was also seen circling the area. Despite the continued search for the teen, tributes have already begun popping up on social media for the talented young basketball player, who travelled to the US last year for a basketball camp. “Man I just saw you last week, it breaks my heart so much, 2025 was gonna big,” one friend wrote. “Had I known last week would be the last time I see you I would’ve embraced you. “My brother, I will see you again. I love you, I’ll always be here for your family, no matter what.” Another wrote: “Miss ya legend”. On Wednesday Inspector Benjamin Campbell of Brisbane Water Police District described the incident as “tragic”. “I feel for the family at this time of year,” he said. “It’s just a timely reminder of how dangerous the rocks can be around the ocean and how everyone has to be really careful.” The president of Central Coast branch of Surf Live Saving NSW Slattery said crews were hoping for a positive outcome. “Our message has been, and always will be, that the flagged locations are the safest place to swim,” he said. “If you are in need of help, that’s the closest resource that we can get to.” Anyone with information about the boy’s whereabouts has been urged to contact Brisbane Water Police or Crime Stoppers.Former Nebraska receiver Malachi Coleman, who redshirted this season after a fruitful freshman campaign, announced his transfer to Minnesota on Tuesday. The 6-foot-4, 190-pound Coleman, a top-100 recruit out of Lincoln East High School, caught eight passes for 139 yards and one touchdown as a true freshman. He sustained an injury that kept him out of spring camp, however, and, after switching jersey numbers from 15 to 80 to accommodate quarterback Dylan Raiola, Coleman appeared in just one game, vs. Rutgers, in 2024. NU also recruited transfers Jahmal Banks and Isaiah Neyor, who had similar size and skillsets, to play over Coleman at his position. Coleman redshirted and will have three seasons of eligibility left as he plays for the Gophers, who visits Oct. 18. Subscribe for the best Husker news & commentary Be the first to know Get local news delivered to your inbox!

The price of bitcoin surpassed $100,000 for the first time on Wednesday, soaring to a fresh high as the world's largest cryptocurrency extended a rally set off by the election of former President Donald Trump. Bitcoin has climbed more than 40% since Election Day, when voters opted for a candidate viewed as friendly toward digital currency. Those gains have far outpaced the stock market. The S &P 500 has increased about 2.4% over that period, while the tech-heavy Nasdaq has jumped 2.6%. On the campaign trail, Trump vowed to bolster the cryptocurrency sector and ease regulations enforced by the Biden administration. Trump also promised to establish the federal government's first National Strategic Bitcoin Reserve. Trump said he would replace Securities and Exchange Commission Chair Gary Gensler, whom many crypto proponents dislike for what they perceive as a robust approach to crypto regulation. Gensler announced that he plans to resign on Jan. 20, 2025, the date of Trump's inauguration. The post-election euphoria has lifted other parts of the crypto sector. Ethereum, the second-largest cryptocurrency, has climbed 27%. Lesser-known dogecoin has skyrocketed about 140%, while litecoin has surged 35%. Shares of Coinbase, a top crypto trading platform, have increased more than 70% since Trump's reelection. The growth in recent weeks extends a remarkable turnabout for the once-beleaguered crypto industry. The sector entered this year bruised after a series of high-profile collapses and company scandals. FTX, a multibillion-dollar cryptocurrency exchange co-founded by Sam Bankman-Fried, collapsed in November 2022. The implosion set off a 17-month legal saga that resulted in the conviction of Bankman-Fried for fraud. In April, Bankman-Fried was sentenced to 25 years in prison. Changpeng Zhao, the founder and former CEO of major cryptocurrency exchange Binance, was sentenced to four months in prison in April after pleading guilty to charges that his platform had enabled illicit financial activity. The reelection of Trump marks the latest in a series of positive developments that have buoyed cryptocurrency this year. Those gains have been propelled, in part, by U.S. approval in January of bitcoin ETFs, or exchange-traded funds. Bitcoin ETFs allow investors to buy into an asset that tracks the price movement of bitcoin, while avoiding the inconvenience and risk of purchasing the crypto coin itself. Last month, options on BlackRock's popular iShares Bitcoin Trust ETF (IBIT) were made available for trading on the Nasdaq. The options, which provide a new avenue for bitcoin investors, allow individuals to commit to buy or sell the ETF at a given price by a specific date. While such investments typically come with additional risk, they can also make large payouts. IBIT inched upward 1% on Friday, reaching a record high of about $56. Bryan Armour, the director of passive strategies research at financial firm Morningstar, attributed the recent crypto surge to investors' anticipation of friendly policy under Trump, as well as the newly available options trading for bitcoin ETFs. Still, the performance of cryptocurrencies, including bitcoin, has proven volatile, Armour added. The price of bitcoin could fall, especially if Trump encounters difficulty following through on his campaign commitments, he said. "As long as the narrative stays positive, there's always room to grow," Armour told ABC News before bitcoin reached $100,000. "I also think campaign promises don't always come to fruition." "It's still a highly volatile asset," Armour added.

Watch out, Eli Lilly and Novo Nordisk . Merck ( MRK -1.48% ) is hungrily looking to take a bite out of the weight-loss drugs market. Amidst an evolving field of competitors, the big pharma is committing a hearty chunk of cash in hopes of becoming a contender. But will that be enough to make it into the next great weight-loss stock? Let's investigate. This new move makes for a trend Merck on Dec. 16 said it had just inked a license agreement with a Chinese biopharma company called Hansoh Pharma that could presage its merits as a weight-loss stock in the coming years. Per the terms of that deal, Merck will get the exclusive worldwide rights to develop and then sell HS-10535, a preclinical-stage candidate that could potentially be useful for treating a few high-profile cardiometabolic disorders, including obesity and perhaps type 2 diabetes. Merck paid Hansoh Pharma $112 million in cash upfront for the asset, and it committed to funding as much as $1.9 billion in development milestone payments, as well as to paying royalties if the candidate is eventually commercialized. So, why is the candidate worth such a large potential outlay? HS-10535 is formulated as a pill that works using the same mechanism of action as Novo Nordisk's injectable diabetes drug Ozempic, but it could have one huge advantage. Ozempic is a peptide, meaning that it's a modestly complex molecule composed of a chain of smaller components called amino acids. In contrast, HS-10535 is a small molecule drug, which, as the name implies, means that it's a relatively simple molecule in the big scheme of things. Small molecules are nearly always much cheaper to produce than peptides, as they have fewer components. Considering Novo Nordisk's recent habit of investing billions and billions into its manufacturing facilities to produce more Ozempic, as well as sibling medicines like its drug Wegovy for treating obesity, if Merck's weight loss candidate is easier to make, it could disrupt the competitive landscape significantly. Merck would be on the hook for less capital expenditure for setting up its manufacturing facilities in the first place, and then it could also undercut Novo Nordisk with a lower-priced medicine, thereby dramatically increasing the chances of it securing a decent market share. Those advantages would still hold true if HS-10535 turns out to be slightly less potent than Ozempic or Wegovy for its intended purposes. And that's why Merck could credibly become the next big weight-loss stock. Keep your expectations restrained for now Before you rush to go buy shares of Merck, appreciate two things about its prospects of becoming a heavyweight in weight loss. First, it will take years of additional research and development (R&D) work before the new candidate has a chance to be approved for sale, assuming it ever is. For investors, most of the time, preclinical programs are rarely worth getting excited about because of the many hurdles they need to overcome before commercialization, and HS-10535 is no exception. Second, Merck is a gargantuan company. Its trailing-12-month (TTM) revenue is $63.1 billion, and by the time the new candidate might be approved, that sum will almost certainly be significantly larger. If HS-10535 ultimately becomes a blockbuster drug that brings in more than $1 billion per year -- which is much more than most medicines ever produce during their peak sales period -- it probably wouldn't move the needle enough for the stock to go up by much. And that's before even testing the relatively safe assumptions about the molecule being inexpensive to produce relative to Ozempic. So, Merck is far from guaranteed to be the next leading weight-loss stock, and until it can show some convincing clinical-stage data about its latest candidate, there's not much reason to buy the stock for its weight-loss programs specifically. Barring any more strategic plays to set it up for entering the market, which could very well occur soon, check back in 18 months.The S&P 500 fell less than 0.1% after spending the day wavering between small gains and losses. The tiny loss ended the benchmark index’s three-day winning streak. The Dow Jones Industrial Average added 0.1% and the Nasdaq composite fell 0.1%. Trading volume was lighter than usual as US markets reopened following the Christmas holiday. Semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, slipped 0.2%. Meta Platforms fell 0.7%, and Amazon and Netflix each fell 0.9%. Tesla was among the biggest decliners in the S&P 500, finishing 1.8% lower. Some tech companies fared better. Chip company Broadcom rose 2.4%, Micron Technology added 0.6% and Adobe gained 0.5%. Health care stocks were a bright spot. CVS Health rose 1.5% and Walgreens Boots Alliance added 5.3% for the biggest gain among S&P 500 stocks. Several retailers also gained ground. Target rose 3%, Ross Stores added 2.3%, Best Buy rose 2.9% and Dollar Tree gained 3.8%. Traders are watching to see whether retailers have a strong holiday season. The day after Christmas traditionally ranks among the top 10 biggest shopping days of the year, as consumers go online or rush to stores to cash in gift cards and raid bargain bins. US-listed shares in Honda and Nissan rose 4.1% and 16.4% respectively. The Japanese car makers announced earlier this week that the two companies are in talks to combine. All told, the S&P 500 fell 2.45 points to 6,037.59. The Dow added 28.77 points to 43,325.80. The Nasdaq fell 10.77 points to close at 20,020.36. Wall Street also got a labour market update. US applications for unemployment benefits held steady last week, though continuing claims rose to the highest level in three years, the Labour Department reported. Treasury yields mostly fell in the bond market. The yield on the 10-year Treasury slipped to 4.58% from 4.59% late on Tuesday. Major European markets were closed, as well as Hong Kong, Australia, New Zealand and Indonesia. Trading was expected to be subdued this week with a thin slate of economic data on the calendar.AP News Summary at 4:42 p.m. EST

Dwarfed by China in shipbuilding, US looks to build its defense base to fend off war